Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	39.26B
Revenue (ttm)	1.37B
Net Income (ttm)	870.39M
Shares Out	616.79M
EPS (ttm)	1.39
PE Ratio	45.75
Forward PE	128.17
Dividend	0.12 (0.19%)
Ex-Dividend Date	Nov 7, 2025

Volume	2,974,854
Average Volume	6,140,216
Open	63.79
Previous Close	63.99
Day's Range	62.58 - 63.96
52-Week Range	19.82 - 83.00
Beta	0.88
RSI	47.25
Earnings Date	Mar 19, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.